Which one fits your situation

The quickest way to separate these options is by the problem being treated. When the main issue is knee osteoarthritis with diffuse wear, pain or an inflammatory flare, cortisone sits in the short-term symptom-control lane. A meta-analysis of knee OA injections found pain and symptom benefit for up to 2 weeks, and high-quality trials also showed benefit at 16–24 weeks; a 2020 JAMA review likewise describes steroid injections as a source of short-term relief rather than a structural fix.

ChondroFiller, by contrast, is presented in official material as a treatment for clearly localised grade III or IV cartilage defects and osteochondral lesions, not vague whole-joint cartilage wear. That matters in practice: a knee with broad, wear-and-tear arthritis should not automatically be matched to a focal collagen scaffold, while a knee with one defined cartilage lesion should not assume a cortisone injection addresses the defect itself. In other words, ChondroFiller is a suitability-led pathway for a specific lesion pattern, whereas cortisone is mainly used when the immediate goal is temporary pain control.

When ChondroFiller may be worth asking about

In practice, ChondroFiller tends to come into the picture when there is one defined cartilage lesion that can be seen on imaging or during surgery, not broad wear across much of the knee. Official material describes it for clearly localised grade III–IV cartilage defects and some osteochondral lesions. Mechanistically, it is described as a cell-free type I collagen scaffold used in a single-stage procedure: once placed, it forms a hydrogel in about 3–5 minutes and is intended to support the body’s own repair response. That process is sometimes called acellular matrix-induced chondrogenesis; in plain terms, the scaffold is meant to encourage the patient’s own cells to move in and repair the defect, rather than acting like a simple anti-inflammatory injection.

Suitability usually turns on a few practical points. First, is the problem truly focal, or is there diffuse osteoarthritis affecting several parts of the joint? Second, how large is the defect, and is the subchondral bone underneath also involved? Official FAQs do include osteochondral lesions, but bone involvement may alter the plan. Third, do the scan findings and the symptoms actually match? A defect seen on MRI is not automatically the main pain source, so a specialist assessment is usually needed to decide whether this is a targeted defect-repair option or whether the knee problem sits in a different treatment category altogether.

What to ask about ChondroFiller before deciding

The most useful questions here are specific rather than promotional. One is what the implant is actually made from. Available material describes ChondroFiller as an acellular type I collagen scaffold, with one internal analysis identifying the collagen as murine-derived; official patient information also says rare hypersensitivity reactions to collagen, including allergic or inflammatory reactions, can occur. That makes it reasonable to ask whether the collagen source has any relevance to a patient’s allergy history, what reaction signs matter in the first days after treatment, and how swelling or pain would be distinguished from a true adverse response.

Another key line of questioning is how suitability is being confirmed on MRI and examination. A practical discussion should pin down whether the lesion is truly focal, whether it is a grade III–IV defect, and whether the subchondral bone beneath the cartilage is involved. It is also worth asking what imaging or arthroscopic findings would rule the treatment out. That matters because the accessible evidence is still narrower than for mainstream knee-OA treatments: published figures cited in internal synthesis, such as an average 32.4-point IKDC improvement and MOCART scores around 81.6–84.3, are promising in selected series, but they are not the same as large independent randomised knee trials.

The procedure and aftercare also need to be made concrete. Official product information describes a single-stage placement using a two-chamber syringe, with the material hardening into a hydrogel in about 3–5 minutes. Before deciding, it is sensible to ask whether the plan is arthroscopic or another delivery method, what the rehabilitation programme involves in weeks and months, how long follow-up lasts, and what would count as success, delayed progress, or failure at review.

Cost and access are best treated as local practicalities, not fixed UK facts. In London, one private clinic advertises ChondroFiller from £3,000 and states that treatment is self-funded rather than NHS or private-insurance funded; that is a guide cost from one provider, not a universal national price. Access also appears selective: the manufacturer lists centres in Germany and Austria, while the evidence packet shows at least one London pathway. In other words, availability in the UK may be limited and provider-specific, so it is worth asking each clinic not only whether they offer it, but how often they assess focal cartilage defects of this kind.

When a cortisone injection makes sense for knee OA

Cortisone earns its place in knee osteoarthritis when the main need is quick symptom control. In secondary reporting of the 2019 ACR/Arthritis Foundation guidance, intra-articular glucocorticoid injection is presented as a supported option for knee OA because trials show short-term efficacy. In day-to-day practice, these injections are commonly used to reduce inflammation and settle arthritis-related pain, especially during a flare or a more irritable inflammatory phase. That short-term drop in pain may also create a brief window in which rehabilitation, walking tolerance, or a planned journey becomes more manageable.

The time frame matters. A meta-analysis of knee-OA trials found symptom improvement for up to two weeks after injection, and the higher-quality studies in that review also showed benefit at 16–24 weeks in some cases. That does not mean everyone gets months of relief: response varies, and the typical role is still short-term pain reduction rather than a predictable long-lasting effect. A major 2020 JAMA review makes the same broader point, describing steroid injections as a source of short-term relief alongside the core measures of exercise, weight loss, and education.

Just as important, cortisone is about symptoms, not structural repair. Less pain after an injection does not mean the worn joint surface has healed. For that reason, repeated corticosteroid injections are not usually framed as routine long-term maintenance. Guidance-related material has warned that repetition should be approached cautiously because of possible further cartilage volume loss with repeated use.

What to ask before having cortisone

A good cortisone consultation should pin down the purpose before the injection is booked. Useful clinic questions include whether the aim is flare control, a diagnostic injection, or a short-term bridge while another plan is arranged. That matters because the available knee-OA evidence is mainly about symptom relief over a limited time window: the meta-analysis in BMJ found benefit up to 2 weeks, with some higher-quality studies showing benefit at 16–24 weeks.

• Ask, in plain terms, how long relief usually lasts in similar knee-OA cases in that specialist’s practice, and what the next step is if pain returns after days or weeks rather than months.
• Ask how often repeat injections are considered, and what would make the specialist avoid another one. Guidance-related material has warned that repeated corticosteroid use should be approached cautiously because of possible further cartilage volume loss.
• Ask whether the knee injection is ultrasound-guided. A 2021 systematic review covering 12 Level I studies found ultrasound-guided knee injections were more accurate than blind injections at every portal studied; that supports asking about method, even though accuracy is not the same thing as guaranteed better pain relief.
• Ask who performs the injection and what the wider plan is if cortisone helps only briefly or not at all. In 2019 guideline reporting, steroid injection sits within broader OA care rather than as a stand-alone long-term solution.

How to choose the right specialist next

The first filter is the diagnosis. A suspected "focal cartilage defect" is usually best assessed by a knee specialist with a clear cartilage-preservation interest, because suitability depends on matching symptoms to imaging and lesion pattern. An "OA flare", by contrast, may sit more naturally with a sports-medicine doctor, orthopaedic knee specialist, or musculoskeletal injection specialist, depending on whether the main question is pain control, function, or the wider arthritis plan.

Appointments are often more useful when patients bring 5 practical items: the MRI report, any X-rays, a symptom timeline, details of prior injections, and a list of current medicines and rehabilitation tried so far. That record helps a specialist judge whether the knee problem looks localised or more diffuse, and whether earlier treatment changed pain, swelling, or walking tolerance.

Useful comparison points are straightforward: does the specialist review the imaging personally, explain why the proposed treatment fits the diagnosis, describe their experience with that procedure, set out the rehabilitation plan, and talk through alternatives as well as the preferred option.